- Home
- CCCC vs NMRA Comparison
CCCC vs NMRA Comparison
Compare CCCC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- NMRA
- Stock Information
- Founded
- CCCC 2015
- NMRA 2019
- Country
- CCCC United States
- NMRA United States
- Employees
- CCCC N/A
- NMRA N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- NMRA
- Sector
- CCCC Health Care
- NMRA
- Exchange
- CCCC Nasdaq
- NMRA Nasdaq
- Market Cap
- CCCC 115.0M
- NMRA 112.8M
- IPO Year
- CCCC 2020
- NMRA 2023
- Fundamental
- Price
- CCCC $1.47
- NMRA $0.81
- Analyst Decision
- CCCC Buy
- NMRA Buy
- Analyst Count
- CCCC 3
- NMRA 8
- Target Price
- CCCC $12.00
- NMRA $9.29
- AVG Volume (30 Days)
- CCCC 943.9K
- NMRA 813.5K
- Earning Date
- CCCC 07-31-2025
- NMRA 05-12-2025
- Dividend Yield
- CCCC N/A
- NMRA N/A
- EPS Growth
- CCCC N/A
- NMRA N/A
- EPS
- CCCC N/A
- NMRA N/A
- Revenue
- CCCC $39,783,000.00
- NMRA N/A
- Revenue This Year
- CCCC N/A
- NMRA N/A
- Revenue Next Year
- CCCC N/A
- NMRA N/A
- P/E Ratio
- CCCC N/A
- NMRA N/A
- Revenue Growth
- CCCC 98.56
- NMRA N/A
- 52 Week Low
- CCCC $1.09
- NMRA $0.61
- 52 Week High
- CCCC $7.66
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- CCCC 51.01
- NMRA 59.11
- Support Level
- CCCC $1.21
- NMRA $0.69
- Resistance Level
- CCCC $1.57
- NMRA $0.73
- Average True Range (ATR)
- CCCC 0.12
- NMRA 0.06
- MACD
- CCCC 0.02
- NMRA 0.02
- Stochastic Oscillator
- CCCC 70.27
- NMRA 79.54
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.